|
| 37871309 | A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. | Blood Adv | 2024 |
| 36194015 | Public health opportunities resulting from sufficient HPV vaccine supply and a single-dose vaccination schedule. | J Natl Cancer Inst | 2023 |
| 37648261 | Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. | J Immunother Cancer | 2023 |
| 37576844 | State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop. | Prev Med Rep | 2023 |
| 37393120 | Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37220752 | Fosmanogepix Therapy of Disseminated Fusarium Infection. | Clin Infect Dis | 2023 |
| 37078412 | Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. | Cancer | 2023 |
| 37379495 | Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. | J Clin Oncol | 2023 |
| 37040086 | Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial. | J Natl Cancer Inst | 2023 |
| 37067240 | Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047. | Cancer Discov | 2023 |
| 37292981 | A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates. | bioRxiv | 2023 |
| 36620882 | HPV42, a "Low-Risk" Type, and Digital Papillary Adenocarcinoma. | Cancer Discov | 2023 |
| 36442769 | Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2023 |
| 36442768 | Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. | Transplant Cell Ther | 2023 |
| 36399715 | North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. | Blood | 2023 |
| 36775201 | Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. | Transplant Cell Ther | 2023 |
| 36423642 | Prospects for preventing cancer with anti-microbial prophylactic vaccines. | Cell Host Microbe | 2023 |
| 36416874 | CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. | Cancer Discov | 2023 |
| 36526260 | Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. | Transplant Cell Ther | 2023 |
| 35941035 | Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions. | Vaccine | 2023 |
| 36315007 | Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. | Blood Adv | 2023 |
| 36370742 | Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. | Lancet Haematol | 2023 |
| 34509319 | Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults. | Blood Rev | 2022 |
| 35709811 | Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. | Lancet Oncol | 2022 |
| 35351898 | HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. | NPJ Vaccines | 2022 |
| 35583292 | Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. | Leuk Lymphoma | 2022 |
| 35700704 | Cancer vaccines. | Cancer Cell | 2022 |
| 35640980 | Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial. | J Natl Cancer Inst | 2022 |
| 35358346 | Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias. | Am J Hematol | 2022 |
| 35749366 | Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. | Proc Natl Acad Sci U S A | 2022 |
| 35748490 | Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. | Transfusion | 2022 |
| 35849791 | Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia. | J Clin Oncol | 2022 |
| 36467792 | Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. | EJHaem | 2022 |
| 36494725 | Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. | J Hematol Oncol | 2022 |
| 36016277 | Harnessing Human Papillomavirus' Natural Tropism to Target Tumors. | Viruses | 2022 |
| 36008233 | Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022. | Vaccine | 2022 |
| 36113532 | Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. | Lancet Glob Health | 2022 |
| 34857420 | Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. | Vaccine | 2022 |
| 35285688 | Chondroitin Sulfate Proteoglycans Are De Facto Cellular Receptors for Human Papillomavirus 16 under High Serum Conditions. | J Virol | 2022 |
| 35081255 | Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. | Blood | 2022 |
| 34864447 | Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay. | Leuk Res | 2022 |
| 35133221 | Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2â¿¿MM-014 trial. | Leuk Lymphoma | 2022 |
| 34802051 | Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. | Br J Cancer | 2022 |
| 32887990 | Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. | J Infect Dis | 2021 |
| 33853825 | Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens. | Cancer Immunol Res | 2021 |
| 33827116 | KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. | Blood | 2021 |
| 33895402 | Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. | Transplant Cell Ther | 2021 |
| 33724305 | Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. | Blood Adv | 2021 |
| 34384438 | Human papillomavirus vaccination in adults: impact, opportunities and challenges - a meeting report. | BMC Proc | 2021 |
| 34590141 | Human Papillomavirus Vaccines. | J Infect Dis | 2021 |